Autolus Therapeutics (NASDAQ:AUTL) Shares Up 13.3% Following Strong Earnings

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) shares traded up 13.3% during trading on Tuesday after the company announced better than expected quarterly earnings. The stock traded as high as $2.3590 and last traded at $2.3450. Approximately 982,049 shares were traded during trading, a decline of 42% from the average session volume of 1,687,173 shares. The stock had previously closed at $2.07.

The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.06. The firm had revenue of $45.69 million for the quarter, compared to the consensus estimate of $38.56 million. Autolus Therapeutics had a negative net margin of 311.98% and a negative return on equity of 128.59%.

Analysts Set New Price Targets

A number of equities analysts recently commented on the stock. Wall Street Zen upgraded shares of Autolus Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday. Jefferies Financial Group upgraded shares of Autolus Therapeutics to a “strong-buy” rating in a research report on Monday, April 20th. Weiss Ratings cut Autolus Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, July 31st. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a report on Monday, August 3rd. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $8.75.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Marex Group plc bought a new stake in shares of Autolus Therapeutics in the 2nd quarter worth approximately $28,000. Independent Advisor Alliance bought a new position in shares of Autolus Therapeutics during the fourth quarter valued at approximately $28,000. GAMMA Investing LLC raised its holdings in shares of Autolus Therapeutics by 115.6% during the second quarter. GAMMA Investing LLC now owns 15,499 shares of the company’s stock valued at $25,000 after acquiring an additional 8,309 shares in the last quarter. SmartHarvest Portfolios LLC purchased a new stake in Autolus Therapeutics in the fourth quarter worth $43,000. Finally, Waverly Advisors LLC bought a new stake in Autolus Therapeutics in the first quarter valued at $37,000. Institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Stock Up 11.4%

The firm’s fifty day moving average is $1.59 and its two-hundred day moving average is $1.55. The firm has a market cap of $614.03 million, a P/E ratio of -2.12 and a beta of 2.07.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.